Drugs / LHC165
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03301896 | Jan 2018 → Jun 2022 | cancer | Novartis Pharmaceuticals | Terminated | No outcome recorded Stop: Business |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LHC165 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03301896 ↗ |
| Route | Other | “LHC165 intratumoral injection” NCT03301896 ↗ |